# A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

> **NCT01321554** · PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 392 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Placebo
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT01321554
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-17
- **Primary completion:** 2013-11-15
- **Final completion:** 2019-03-19
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01321554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01321554, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01321554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*